Decipher Biosciences, Inc. (DECI)
| Market Cap | n/a |
| Revenue (ttm) | 33.26M |
| Net Income (ttm) | -5.83M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Decipher Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.
About DECI
Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers. Our novel prostate cancer genomic testing products, Decipher Biopsy and Decipher RP, provide valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Our differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis,... [Read more...]
| Industry Medical Devices | IPO Date Pending |
| CEO Tina S. Nova, Ph.D. | Employees 95 |
| Stock Exchange NASDAQ | Ticker Symbol DECI |
Financial Performance
In 2019, DECI's revenue was $16.52 million, an increase of 36.89% compared to the previous year's $12.07 million. Losses were -$18.45 million, -38.37% less than in 2018.